Dyslipidemia Drugs Market Report

Global and Region Dyslipidemia Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：138
  • REPORT CODE：GMM924931
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual. 

    The report details the trend, potential and market size of Dyslipidemia Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Dyslipidemia Drugsmarket, defines the market attractiveness level of Dyslipidemia Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Dyslipidemia Drugs industry, describes the types of Dyslipidemia Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Dyslipidemia Drugs market and the development prospects and opportunities of Dyslipidemia Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Dyslipidemia Drugs market in Chapter 13.

    By Player:

    • Cipla

    • CKD Bio

    • Amarin Corporation

    • Catabasis Pharmaceuticals

    • Bristol-Myers Squibb

    • Merck

    • JW Pharmaceuticals

    • Amgen

    • Daiichi Sankyo

    • Sanofi

    • Cerenis

    • Lupin Pharmaceuticals

    • AstraZeneca

    • Eli Lilly

    • Kadmon Pharmaceuticals

    • GlaxoSmithKline

    • CJ HealthCare

    • Pfizer

    • Alnylam Pharmaceuticals

    • Esperion Therapeutics

    • Daewoong Pharmaceutical

    By Type:

    • Statins

    • Cholesterol absorption inhibitors

    • Dyslipidemia injectable

    By End-User:

    • Hospitals and Clinics

    • Medical Laboratories

    • Drug Stores

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Dyslipidemia Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Dyslipidemia Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Dyslipidemia Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Dyslipidemia Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Dyslipidemia Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Dyslipidemia Drugs Consumption (2017-2022)

    • 7.2 United States Dyslipidemia Drugs Consumption (2017-2022)

    • 7.3 Europe Dyslipidemia Drugs Consumption (2017-2022)

    • 7.4 China Dyslipidemia Drugs Consumption (2017-2022)

    • 7.5 Japan Dyslipidemia Drugs Consumption (2017-2022)

    • 7.6 India Dyslipidemia Drugs Consumption (2017-2022)

    • 7.7 South Korea Dyslipidemia Drugs Consumption (2017-2022)

    8 Region and Country-wise Dyslipidemia Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Dyslipidemia Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Dyslipidemia Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Dyslipidemia Drugs Consumption Forecast (2022-2028)

    • 8.4 China Dyslipidemia Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Dyslipidemia Drugs Consumption Forecast (2022-2028)

    • 8.6 India Dyslipidemia Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Dyslipidemia Drugs Consumption Forecast (2022-2028)

    9 Global Dyslipidemia Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Dyslipidemia Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Statins Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Cholesterol absorption inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Dyslipidemia injectable Consumption and Growth Rate (2017-2022)

    • 9.2 Global Dyslipidemia Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals and Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Medical Laboratories Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Drug Stores Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Dyslipidemia Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Dyslipidemia Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Statins Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Cholesterol absorption inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Dyslipidemia injectable Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Dyslipidemia Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals and Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Medical Laboratories Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Drug Stores Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Dyslipidemia Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Dyslipidemia Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Dyslipidemia Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Dyslipidemia Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Dyslipidemia Drugs Market Competitive Analysis

    • 14.1 Cipla

      • 14.1.1 Cipla Company Details

      • 14.1.2 Cipla Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Cipla Dyslipidemia Drugs Product and Service

    • 14.2 CKD Bio

      • 14.2.1 CKD Bio Company Details

      • 14.2.2 CKD Bio Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 CKD Bio Dyslipidemia Drugs Product and Service

    • 14.3 Amarin Corporation

      • 14.3.1 Amarin Corporation Company Details

      • 14.3.2 Amarin Corporation Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Amarin Corporation Dyslipidemia Drugs Product and Service

    • 14.4 Catabasis Pharmaceuticals

      • 14.4.1 Catabasis Pharmaceuticals Company Details

      • 14.4.2 Catabasis Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Catabasis Pharmaceuticals Dyslipidemia Drugs Product and Service

    • 14.5 Bristol-Myers Squibb

      • 14.5.1 Bristol-Myers Squibb Company Details

      • 14.5.2 Bristol-Myers Squibb Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Bristol-Myers Squibb Dyslipidemia Drugs Product and Service

    • 14.6 Merck

      • 14.6.1 Merck Company Details

      • 14.6.2 Merck Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Merck Dyslipidemia Drugs Product and Service

    • 14.7 JW Pharmaceuticals

      • 14.7.1 JW Pharmaceuticals Company Details

      • 14.7.2 JW Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 JW Pharmaceuticals Dyslipidemia Drugs Product and Service

    • 14.8 Amgen

      • 14.8.1 Amgen Company Details

      • 14.8.2 Amgen Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Amgen Dyslipidemia Drugs Product and Service

    • 14.9 Daiichi Sankyo

      • 14.9.1 Daiichi Sankyo Company Details

      • 14.9.2 Daiichi Sankyo Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Daiichi Sankyo Dyslipidemia Drugs Product and Service

    • 14.10 Sanofi

      • 14.10.1 Sanofi Company Details

      • 14.10.2 Sanofi Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Sanofi Dyslipidemia Drugs Product and Service

    • 14.11 Cerenis

      • 14.11.1 Cerenis Company Details

      • 14.11.2 Cerenis Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Cerenis Dyslipidemia Drugs Product and Service

    • 14.12 Lupin Pharmaceuticals

      • 14.12.1 Lupin Pharmaceuticals Company Details

      • 14.12.2 Lupin Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Lupin Pharmaceuticals Dyslipidemia Drugs Product and Service

    • 14.13 AstraZeneca

      • 14.13.1 AstraZeneca Company Details

      • 14.13.2 AstraZeneca Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 AstraZeneca Dyslipidemia Drugs Product and Service

    • 14.14 Eli Lilly

      • 14.14.1 Eli Lilly Company Details

      • 14.14.2 Eli Lilly Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Eli Lilly Dyslipidemia Drugs Product and Service

    • 14.15 Kadmon Pharmaceuticals

      • 14.15.1 Kadmon Pharmaceuticals Company Details

      • 14.15.2 Kadmon Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Kadmon Pharmaceuticals Dyslipidemia Drugs Product and Service

    • 14.16 GlaxoSmithKline

      • 14.16.1 GlaxoSmithKline Company Details

      • 14.16.2 GlaxoSmithKline Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 GlaxoSmithKline Dyslipidemia Drugs Product and Service

    • 14.17 CJ HealthCare

      • 14.17.1 CJ HealthCare Company Details

      • 14.17.2 CJ HealthCare Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 CJ HealthCare Dyslipidemia Drugs Product and Service

    • 14.18 Pfizer

      • 14.18.1 Pfizer Company Details

      • 14.18.2 Pfizer Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 Pfizer Dyslipidemia Drugs Product and Service

    • 14.19 Alnylam Pharmaceuticals

      • 14.19.1 Alnylam Pharmaceuticals Company Details

      • 14.19.2 Alnylam Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.19.3 Alnylam Pharmaceuticals Dyslipidemia Drugs Product and Service

    • 14.20 Esperion Therapeutics

      • 14.20.1 Esperion Therapeutics Company Details

      • 14.20.2 Esperion Therapeutics Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.20.3 Esperion Therapeutics Dyslipidemia Drugs Product and Service

    • 14.21 Daewoong Pharmaceutical

      • 14.21.1 Daewoong Pharmaceutical Company Details

      • 14.21.2 Daewoong Pharmaceutical Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.21.3 Daewoong Pharmaceutical Dyslipidemia Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Dyslipidemia Drugs

    • Figure Dyslipidemia Drugs Picture

    • Table Global Dyslipidemia Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Dyslipidemia Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Dyslipidemia Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Dyslipidemia Drugs Consumption by Country (2017-2022)

    • Figure United States Dyslipidemia Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Dyslipidemia Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Dyslipidemia Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Dyslipidemia Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Dyslipidemia Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Dyslipidemia Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Dyslipidemia Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Dyslipidemia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Dyslipidemia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Dyslipidemia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Dyslipidemia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Dyslipidemia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Dyslipidemia Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Statins Consumption and Growth Rate (2017-2022)

    • Figure Global Cholesterol absorption inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Dyslipidemia injectable Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals and Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Medical Laboratories Consumption and Growth Rate (2017-2022)

    • Figure Global Drug Stores Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Statins Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cholesterol absorption inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Dyslipidemia injectable Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals and Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Medical Laboratories Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Drug Stores Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Dyslipidemia Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Dyslipidemia Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table Cipla (Foundation Year, Company Profile and etc.)

    • Table Cipla Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cipla Dyslipidemia Drugs Product and Service

    • Table CKD Bio (Foundation Year, Company Profile and etc.)

    • Table CKD Bio Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table CKD Bio Dyslipidemia Drugs Product and Service

    • Table Amarin Corporation (Foundation Year, Company Profile and etc.)

    • Table Amarin Corporation Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amarin Corporation Dyslipidemia Drugs Product and Service

    • Table Catabasis Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Catabasis Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Catabasis Pharmaceuticals Dyslipidemia Drugs Product and Service

    • Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Dyslipidemia Drugs Product and Service

    • Table Merck (Foundation Year, Company Profile and etc.)

    • Table Merck Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Dyslipidemia Drugs Product and Service

    • Table JW Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table JW Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table JW Pharmaceuticals Dyslipidemia Drugs Product and Service

    • Table Amgen (Foundation Year, Company Profile and etc.)

    • Table Amgen Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Dyslipidemia Drugs Product and Service

    • Table Daiichi Sankyo (Foundation Year, Company Profile and etc.)

    • Table Daiichi Sankyo Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi Sankyo Dyslipidemia Drugs Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Dyslipidemia Drugs Product and Service

    • Table Cerenis (Foundation Year, Company Profile and etc.)

    • Table Cerenis Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cerenis Dyslipidemia Drugs Product and Service

    • Table Lupin Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Lupin Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lupin Pharmaceuticals Dyslipidemia Drugs Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Dyslipidemia Drugs Product and Service

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Dyslipidemia Drugs Product and Service

    • Table Kadmon Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Kadmon Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kadmon Pharmaceuticals Dyslipidemia Drugs Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Dyslipidemia Drugs Product and Service

    • Table CJ HealthCare (Foundation Year, Company Profile and etc.)

    • Table CJ HealthCare Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table CJ HealthCare Dyslipidemia Drugs Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Dyslipidemia Drugs Product and Service

    • Table Alnylam Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Alnylam Pharmaceuticals Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alnylam Pharmaceuticals Dyslipidemia Drugs Product and Service

    • Table Esperion Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Esperion Therapeutics Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Esperion Therapeutics Dyslipidemia Drugs Product and Service

    • Table Daewoong Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Daewoong Pharmaceutical Dyslipidemia Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daewoong Pharmaceutical Dyslipidemia Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US